Moderna’s first attempt to expand its commercial activities beyond COVID-19 vaccines, its respiratory syncytial virus (RSV) shot, has suffered a delay in the US. The company said the FDA would ...
Moderna on Friday said the Food and Drug Administration has postponed an approval decision on its experimental vaccine for ...
US regulators’ decision on whether to approve Moderna Inc.’s vaccine for RSV has been delayed due to “administrative constraints” at the Food and Drug Administration, as the company works ...
, opens new tab respiratory syncytial virus (RSV) vaccine due to "administrative constraints" and will complete the review by the end of this month, the company said on Friday. Moderna's shares ...
Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.
Ever since the COVID-19 pandemic began to ease, Moderna has weathered a sharp revenue downturn. But a new FDA approval shows that the company's scientific engine is no one trick pony. Moderna's ...
RESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes ...
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.
Moderna’s shot is the third RSV vaccine for people 60 and older that’s gotten the green light from the FDA and the first mRNA vaccine among them. It’s the company’s second product to ...
, opens new tab respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product. Moderna's vaccine was approved for ...